- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
A PCT chief pharmacist challenged Takeda’s PROactive study messaging in a DHP letter (primary endpoint not significant; secondary endpoints and HF data…
Anonymous complaints alleged inappropriate hospitality and a “nexus” with organisers at a schizophrenia meeting sponsored by Otsuka and BMS. Panel found the…
Public complaint said MabThera BMJ ad misled by showing an athlete and using “Recommended by NICE” with a medal. PMCPA ruled no…
Crestor ad alleged to mislead by implying direct comparison with simvastatin and criticising it. Panel ruled no breach of Clauses 7.2–7.4, but…
A GP complained Bayer’s “SortEDin10” ED awareness ads implied ED could be “sorted” in a 10‑minute consultation. The Panel found the slogan…
A Big Issue schizophrenia awareness ad claimed modern treatments offer a “real chance of recovery”. PMCPA said lay readers could take this…
Bayer admitted a leaflet that should have been withdrawn under an undertaking was still displayed at BAUS. PMCPA found breaches of Clauses…
Pfizer hospital reps were set targets implying 8 proactive calls per target doctor per year. The Panel said the planning documents advocated…
A hospital consultant alleged a Lilly representative implied an educational post grant could be threatened unless Lilly insulin use increased. Lilly said…
Thame sent clinicians a legalistic letter urging a switch from Sodibic to Thamicarb, implying MHRA backing and prosecution. PMCPA ruled multiple breaches;…
PMCPA Director case on clinical trial disclosure for Picato involving Leo. Ruled no breach because the matter was outwith the scope of…
Anonymous complaint about a meeting advertised on LinkedIn. PMCPA concluded no breach because the matter was outwith the scope of the ABPI…
A GP alleged Pfizer’s BMJ Rapid Response was disguised promotion of Lipitor and should include PI and AE reporting. The Panel found…
Servier’s Protelos promotion was challenged over “first/only dual action” claims. Panel found claims misleading, but the Appeal Board ruled the statements of…
BMS alleged Novartis used the ENACT nilotinib expanded access programme and website as disguised promotion of an unlicensed medicine. The Panel found…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.